Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025

Core Insights - Fulcrum Therapeutics has completed enrollment in the 12 mg dose cohort of the Phase 1b PIONEER trial for pociredir in sickle cell disease (SCD) and has initiated the 20 mg dose cohort [1][6] - The company plans to share data from the 12 mg dose cohort in early Q3 2025 and from the 20 mg dose cohort by the end of 2025 [2][5] Recent Business Highlights - The PIONEER trial shows strong engagement with 16 patients enrolled in the 12 mg cohort and adherence rates exceeding 90% [6] - Two abstracts related to pociredir have been accepted for presentation at the 2025 European Hematology Association Congress [6] - The company is advancing its program for inherited aplastic anemias and plans to submit an IND for Diamond-Blackfan anemia in Q4 2025 [6] Financial Results - As of March 31, 2025, Fulcrum had $226.6 million in cash, cash equivalents, and marketable securities, down from $241.0 million at the end of 2024 [5][14] - Research and development expenses for Q1 2025 were $13.4 million, a decrease from $19.8 million in Q1 2024, primarily due to the discontinuation of the losmapimod program [5][15] - General and administrative expenses decreased to $7.0 million in Q1 2025 from $10.1 million in Q1 2024, attributed to reduced employee compensation costs [5][15] - The net loss for Q1 2025 was $17.7 million, compared to a net loss of $26.9 million in Q1 2024 [5][15] Cash Position and Guidance - Fulcrum expects its current cash position to fund operations into at least 2027 [7]